A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. Of the 113 patients who applied topical masoprocol twice a day for 14 to 28 days, there was a mean decrease in actinic keratoses from 15.0 to 5.4 and a median percent reduction from baseline actinic keratosis count of 71.4% at the 1-month follow-up visit. Comparable numbers for the vehicle-treated group were 13.4 to 11.1 actinic keratoses and 4.3% median percent reduction. Irritation, as manifested by erythema or flaking, occurred in 61.5% of topical masoprocol-treated patients versus 26.7% of those treated with vehicle and did not correlate with clinical response. Topical masoprocol appears to be useful in the treatment of actinic keratoses.

Full Text

Duke Authors

Cited Authors

  • Olsen, EA; Abernethy, ML; Kulp-Shorten, C; Callen, JP; Glazer, SD; Huntley, A; McCray, M; Monroe, AB; Tschen, E; Wolf, JE

Published Date

  • May 1991

Published In

Volume / Issue

  • 24 / 5 Pt 1

Start / End Page

  • 738 - 743

PubMed ID

  • 1869646

International Standard Serial Number (ISSN)

  • 0190-9622

Digital Object Identifier (DOI)

  • 10.1016/0190-9622(91)70113-g


  • eng

Conference Location

  • United States